Gerlach, Manfred

[["dc.bibliographiccitation.firstpage","958"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","960"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Unterecker, Stefan"],["dc.contributor.author","Hefner, Gudrun"],["dc.contributor.author","Baumann, Pierre"],["dc.contributor.author","Gründer, Gerd"],["dc.contributor.author","Bergemann, Niels"],["dc.contributor.author","Clement, Hans-Willi"],["dc.contributor.author","Conca, Andreas"],["dc.contributor.author","Deckert, Jürgen"],["dc.contributor.author","Domschke, Katharina"],["dc.contributor.author","Eckermann, Gabriel"],["dc.contributor.author","Egberts, Karin"],["dc.contributor.author","Gerlach, Manfred"],["dc.contributor.author","Greiner, Christine"],["dc.contributor.author","Haen, Ekkehard"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Helmer, Renate"],["dc.contributor.author","Janssen, Ger"],["dc.contributor.author","Jaquenoud, Eveline"],["dc.contributor.author","Laux, Gerd"],["dc.contributor.author","Messer, Thomas"],["dc.contributor.author","Mössner, Rainald"],["dc.contributor.author","Müller, Matthias J."],["dc.contributor.author","Paulzen, Michael"],["dc.contributor.author","Pfuhlmann, Bruno"],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Saria, Alois"],["dc.contributor.author","Schoppek, Bernd"],["dc.contributor.author","Schoretsanitis, Georgios"],["dc.contributor.author","Schwarz, Markus"],["dc.contributor.author","Gracia, Margarethe Silva"],["dc.contributor.author","Stegmann, Benedikt"],["dc.contributor.author","Steimer, Werner"],["dc.contributor.author","Stingl, Julia C."],["dc.contributor.author","Uhr, Manfred"],["dc.contributor.author","Ulrich, Sven"],["dc.contributor.author","Waschgler, Roland"],["dc.contributor.author","Zernig, Gerald"],["dc.contributor.author","Zurek, Gabriele"],["dc.contributor.author","Hiemke, Christoph"],["dc.date.accessioned","2020-12-10T14:08:38Z"],["dc.date.available","2020-12-10T14:08:38Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00115-019-0766-7"],["dc.identifier.eissn","1433-0407"],["dc.identifier.issn","0028-2804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70504"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.iserratumof","/handle/2/70500"],["dc.title","Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie"],["dc.title.alternative","Erratum to: Therapeutic drug monitoring in neuropsychopharmacology. Summary of the consensus guidelines 2017 of the TDM task force of the AGNP"],["dc.title.subtitle","Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","erratum_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","471"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","AIDS Research and Human Retroviruses"],["dc.bibliographiccitation.lastpage","477"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Koutsilieri, Eleni"],["dc.contributor.author","Sopper, Sieghart"],["dc.contributor.author","Heinemann, Thoralf"],["dc.contributor.author","Scheller, Carsten"],["dc.contributor.author","Lan, Jing"],["dc.contributor.author","Stahl-Hennig, Christiane"],["dc.contributor.author","Meulen, Volker Ter"],["dc.contributor.author","Riederer, Peter"],["dc.contributor.author","Gerlach, Manfred"],["dc.date.accessioned","2022-10-06T13:34:40Z"],["dc.date.available","2022-10-06T13:34:40Z"],["dc.date.issued","1999"],["dc.identifier.doi","10.1089/088922299311222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/115968"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-602"],["dc.relation.eissn","1931-8405"],["dc.relation.issn","0889-2229"],["dc.relation.orgunit","Deutsches Primatenzentrum"],["dc.title","Involvement of Microglia in Cerebrospinal Fluid Glutamate Increase in SIV-Infected Rhesus Monkeys (Macaca mulatta)"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2474"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Current Pharmaceutical Design"],["dc.bibliographiccitation.lastpage","2483"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Bock, Nathalie"],["dc.contributor.author","Gerlach, Manfred"],["dc.contributor.author","Rothenberger, Aribert"],["dc.date.accessioned","2021-06-01T10:48:34Z"],["dc.date.available","2021-06-01T10:48:34Z"],["dc.date.issued","2010"],["dc.description.abstract","In recent years an increased use of psychotropic medication in children has been observed, but little is known about the influence of this medication on brain maturation. Probably, because of methodological problems and/or ethical aspects. It means that only naturalistic observational studies might allow to get some insight in humans. But even animal studies touching this issue are scarce and heterogeneous. Nevertheless, postnatal brain development is highly sensitive to the effects of psychotropic drugs, either in the short- and/or long-term. Therefore, more and better information is needed. The main targets of psychotropic drugs are the monoaminergic transmitter systems that are related to brain networks for motor behavior, motivation, emotion, and cognition. In order to elucidate the mechanisms of drug development interactions and their long-term consequences on brain and behavior, animal studies might provide a good basis for a better understanding and guidance of research in humans. Hence, this article reviews the possible influence of those psychotropic drugs on postnatal brain development in animals (mostly rats and rodents) which are widely used to treat common psychiatric disorders in children and adolescents like depression and attention-deficit/hyperactivity disorder (ADHD). Moreover this review refers to the obvious problems of the available animal studies (including experimental animal models of child psychiatric disorders) which seem to be of limited value in translating experimental knowledge to the complexity of clinical understanding and practice."],["dc.identifier.doi","10.2174/138161210791959836"],["dc.identifier.isi","000280473600009"],["dc.identifier.pmid","20513226"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85981"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1381-6128"],["dc.title","Postnatal Brain Development and Psychotropic Drugs. Effects on Animals and Animal Models of Depression and Attention-Deficit/Hyperactivity Disorder"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","972141"],["dc.bibliographiccitation.journal","Frontiers in Psychiatry"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Eichentopf, Luzie; 1Department of Molecular Neuroimaging, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany"],["dc.contributor.affiliation","Hiemke, Christoph; 2Department of Psychiatry and Psychotherapy, Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany"],["dc.contributor.affiliation","Conca, Andreas; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Engelmann, Jan; 5Department of Psychiatry and Psychotherapy, Johannes Gutenberg University Medical Center Mainz, Mainz, Germany"],["dc.contributor.affiliation","Gerlach, Manfred; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Havemann-Reinecke, Ursula; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Hefner, Gudrun; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Florio, Vincenzo; 9Department of Psychiatry, Comprensorio Sanitario di Bolzano, Bolzano, Italy"],["dc.contributor.affiliation","Kuzin, Maxim; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Lieb, Klaus; 11Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany"],["dc.contributor.affiliation","Reis, Margareta; 12Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden"],["dc.contributor.affiliation","Riemer, Thomas G.; 14Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany"],["dc.contributor.affiliation","Serretti, Alessandro; 15Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"],["dc.contributor.affiliation","Schoretsanitis, Georgios; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Zernig, Gerald; 3Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)-Work Group “Therapeutic Drug Monitoring”, Nürnberg, Germany"],["dc.contributor.affiliation","Gründer, Gerhard; 1Department of Molecular Neuroimaging, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany"],["dc.contributor.affiliation","Hart, Xenia M.; 1Department of Molecular Neuroimaging, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany"],["dc.contributor.author","Eichentopf, Luzie"],["dc.contributor.author","Hiemke, Christoph"],["dc.contributor.author","Conca, Andreas"],["dc.contributor.author","Engelmann, Jan"],["dc.contributor.author","Gerlach, Manfred"],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.contributor.author","Hefner, Gudrun"],["dc.contributor.author","Florio, Vincenzo"],["dc.contributor.author","Kuzin, Maxim"],["dc.contributor.author","Lieb, Klaus"],["dc.contributor.author","Hart, Xenia M."],["dc.date.accessioned","2022-12-01T08:31:36Z"],["dc.date.available","2022-12-01T08:31:36Z"],["dc.date.issued","2022-10-17"],["dc.date.updated","2022-11-11T13:12:31Z"],["dc.description.abstract","Introduction\r\n A titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram. Furthermore, the recommended reference range disagrees with mean steady state concentrations (11–21 ng/ml) that are expected under the approved dose range (10–20 mg/day). This work systematically investigated the relationships between escitalopram dose, blood levels, clinical effects, and serotonin transporter occupancy.\r\n \r\n \r\n Methods\r\n Following our previously published methodology, relevant articles were systematically searched and reviewed for escitalopram.\r\n \r\n \r\n Results\r\n Of 1,032 articles screened, a total of 30 studies met the eligibility criteria. The included studies investigated escitalopram blood levels in relationship to clinical effects (9 studies) or moderating factors on escitalopram metabolism (12 studies) or serotonin transporter occupancy (9 studies). Overall, the evidence for an escitalopram concentration/effect relationship is low (level C).\r\n \r\n \r\n Conclusion\r\n Based on our findings, we propose a target range of 20–40 ng/ml for antidepressant efficacy of escitalopram. In maintenance treatment, therapeutic response is expected, when titrating patients above the lower limit. The lower concentration threshold is strongly supported by findings from neuroimaging studies. The upper limit for escitalopram’s reference range rather reflects a therapeutic maximum than a tolerability threshold, since the incidence of side effects in general is low. Concentrations above 40 ng/ml should not necessarily result in dose reductions in case of good clinical efficacy and tolerability. Dose-related escitalopram concentrations in different trials were more than twice the expected concentrations from guideline reports.\r\n \r\n \r\n Systematic review registration\r\n \r\n [\r\n https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=215873\r\n ], identifier [CRD42020215873]."],["dc.identifier.doi","10.3389/fpsyt.2022.972141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118213"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1664-0640"],["dc.relation.isreplacedby","hdl:2/118213"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]